SCHEMBL2713615

SCHEMBL2713615

CON(C)C(=O)c1cc(C)nc(O)c1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MLYCD O95822 1/20 0.39
CLK1 P49759 1/20 0.36
DYRK1A Q13627 1/20 0.36
DYRK1B Q9Y463 1/20 0.36
TRPM8 Q7Z2W7 2/20 0.36
ICAM1 P05362 1/20 0.33
SELE P16581 1/20 0.33
KDM4E B2RXH2 3/20 0.33
MEN1 O00255 2/20 0.33
KMT2A Q03164 2/20 0.33
HPGD P15428 1/20 0.33
RXFP1 Q9HBX9 1/20 0.33
HPGDS O60760 2/20 0.32
MAPT P10636 2/20 0.32
RECQL P46063 1/20 0.32
GAA P10253 1/20 0.32
SMN1; SMN2 Q16637 1/20 0.31
POLB P06746 1/20 0.31
GPBAR1 Q8TDU6 1/20 0.31
ALDH1A1 P00352 2/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL361909 0.90 MLYCD (0.42) MLYCDCLK1DYRK1ADYRK1BTRPM8
SCHEMBL3926252 0.82 GPBAR1 (0.45) MLYCDCLK1DYRK1ADYRK1BSMN1; SMN2
SCHEMBL21742932 0.77 KDM5A (0.41) MLYCDCLK1DYRK1ADYRK1BPOLB
SCHEMBL1424986 0.76 FAAH (0.39) MLYCDCLK1DYRK1ADYRK1BGAA
SCHEMBL21326545 0.75 CA12 (0.53) KDM4EMEN1KMT2AHPGDRXFP1
SCHEMBL30015842 0.75 CA12 (0.53) KDM4EMEN1KMT2AHPGDRXFP1
SCHEMBL4719735 0.74 TPMT (0.46) MLYCDCLK1DYRK1ADYRK1BICAM1
SCHEMBL6493529 0.74 MLYCD (0.45) MLYCDCLK1DYRK1ADYRK1BICAM1
SCHEMBL1367620 0.74 MLYCD (0.41) MLYCDCLK1DYRK1ADYRK1BTRPM8
SCHEMBL8282923 0.74 MLYCD (0.41) MLYCDCLK1DYRK1ADYRK1BTRPM8

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2630122-B1 ARYLAMIDE DERIVATIVES AS TTX-S BLOCKERS RAQUALIA PHARMA INC (JP) 2016-11-30 EP disclosed
US-9302991-B2 Arylamide derivatives as TTX-S blockers RAQUALIA PHARMA INC. (JP) 2016-04-05 US disclosed
US-20140336377-A1 ARYLAMIDE DERIVATIVES AS TTX-S BLOCKERS RAQUALIA PHARMA INC. (JP) 2014-11-13 US disclosed
EP-2630122-A1 ARYLAMIDE DERIVATIVES AS TTX-S BLOCKERS RaQualia Pharma Inc (JP) 2013-08-28 EP disclosed
WO-2012053186-A1 ARYLAMIDE DERIVATIVES AS TTX-S BLOCKERS RAQUALIA PHARMA INC. (JP) 2012-04-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140336377-A1 ARYLAMIDE DERIVATIVES AS TTX-S BLOCKERS SCN2B, SCN1B, SCN2A MLYCD 4116/4885CLK1 4828/4885DYRK1A 3666/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.